肠道微生物组在慢性肾脏疾病中的作用和姜黄素的潜在治疗策略

Chronic kidney disease (CKD) is a major disease that seriously endangers human health and life, with high morbidity and mortality. It is an urgent problem to find effective treatment methods to control the development, many studies have found that intestinal flora and its metabolites are closely related to the occurrence and development of CKD. Curcumin (CUR) have been shown to be effective in acute kidney injury and CKD. However, CUR has extremely low bioavailability after oral administration and absorption, and the material basis and process mechanism of its pharmacological effects have been controversial. In recent years, the regulatory effect of CUR on intestinal microecology has been extensively studied. It has been reported that high concentrations of CUR exist in the gastrointestinal tract after oral administration, which may mainly play a direct regulatory role in the gastrointestinal tract. Furthermore, a newly proposed theory suggests that CUR may exert its renal protective effects indirectly by affecting the "gut-kidney axis". Therefore, this review will mainly discuss the close relationship between gut microbiota and its metabolites with CKD, and the therapeutic strategies of CUR targeting gut microbiota to improve CKD, including regulating the composition of gut microbiota, protecting the intes-tinal mucosal barrier, regulating intestinal inflammatory signal transduction, increasing the content of short-chain fatty acids (SCFAs), and enhancing of gut microbiota-mediated biotransformation of CUR. The future prospect is assessed by us that the metabolites of CUR and microorganisms can beneficially delay the onset and progression of CKD by targeting the intestinal flora and propose the unresolved scientific issues in this area.